Trial · NCT06033820
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
NCT06033820, Phase 2, Unknown, RenJi Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL. Trials, record NCT06033820. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06033820
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
- NCT number
- NCT06033820
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- RenJi Hospital
- Conditions
- Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
- Interventions
- ZR2-ICE
- First posted
- 2023-09-13
- Last updated
- 2024-03-13
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | 9 weeks | To evaluate the efficacy in terms of objective response rate including CR and PR rate after three cycles of ZR2-ICE |
| Secondary | Complete remission rate (CR) | 9 weeks | To evaluate the efficacy in terms of Complete Response Rate after three cycles of ZR2-ICE |
| Secondary | DOR | Up to 2 years | Among participants who experience an objective response, DOR is defined as the date of their first objective response (which is subsequently confirmed) to disease progression |
| Secondary | Progression-free survival | Up to 2 years | Progression-free survival is defined as the time from enrolment to progression or death due to any cause. The distribution of PFS will be estimated using the method of Kaplan-Meier. |
| Secondary | Overall survival | Up to 2 years | Overall survival is defined as the time from enrolment to death due to any cause. |
| Secondary | Safety Management Study | Up to 100 days | Incidence of Treatment-Emergent Adverse Events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06033820
GET https://conductscience.org/api/trials/v1/NCT06033820/registered